Cargando…
US, EU, and Japanese Regulatory Guidelines for Development of Drugs for Treatment of Alzheimer’s Disease: Implications for Global Drug Development
Drug development guidelines from regulatory authorities provide important information to sponsors on requirements for clinical evidence needed to support approval of new drugs. In the field of Alzheimer’s disease (AD), recently published guidelines are available from EU, US, and Japanese regulatory...
Autores principales: | Morant, Anne Vinther, Vestergaard, Henrik Tang, Lassen, Anders Blædel, Navikas, Vaidrius |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7359941/ https://www.ncbi.nlm.nih.gov/pubmed/32043310 http://dx.doi.org/10.1111/cts.12755 |
Ejemplares similares
-
New Drug and Biologics Approvals in 2019: A Systematic Analysis of Patient Experience Data in FDA Drug Approval Packages and Product Labels
por: Schultz-Knudsen, Katrine, et al.
Publicado: (2020) -
Characteristics of Single Pivotal Trials Supporting Regulatory Approvals of Novel Non‐orphan, Non‐oncology Drugs in the European Union and United States from 2012−2016
por: Morant, Anne Vinther, et al.
Publicado: (2019) -
Local therapy with CpG motifs in a murine model of allergic airway inflammation in IFN-β knock-out mice
por: Matheu, Victor, et al.
Publicado: (2005) -
Mandatory requirements for pediatric drug development in the EU and the US for novel drugs—A comparative study
por: Christiansen, Helle, et al.
Publicado: (2022) -
The role of globalization in drug development and access to orphan drugs: orphan drug legislation in the US/EU and in Latin America
por: Arnold, Renée J.G., et al.
Publicado: (2015)